Clinical Trial

GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

Study acronym: AID-JUNCT
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 26, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Blood glucose management in type 1 diabetes (T1D) remains a challenge, with only \~30% of adults within the recommended consensus guidelines. Novel drugs like glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs have emerged as promising add-ons to insulin in T1D. This application has been designed to test in a prospective study whether adding a new medicine called tirzepatide (GIP/GLP-1RA) to the usual insulin therapy would make a difference for people with T1D in terms of better glucose control.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-10-03; most recent amendment 2026-01-22.
Status change: Not Yet Recruiting → Recruiting 2025-06-03
Trial Details
NCT Number NCT06630585
Lead Sponsor University of Bern
Collaborators: Kantonsspital Olten, Luzerner Kantonsspital, Clinique des Grangettes, Chêne-Bougeries
Conditions Type 1 Diabetes (T1D)
Enrollment 42 participants
Start Date 2025-02-14
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-26